Elms Steve insider trades
Elms Steve has filed 18 Form 4s with the SEC that we hold, for Adma Biologics, INC. (ADMA) (Director), Marker Therapeutics, Inc. (MRKR) (Director) and ELEV (Director). Across all of them we count 3 purchases worth $252.9K and 8 sales worth $18.0M reported on Form 4. In the last 12 months: 2 purchases ($217.4K) and 0 sales ($0). The largest single trade was a sale of 194,749 shares of Adma Biologics, INC. worth $3.9M, dated 2025-06-16. The first filing on our record is dated 2022-03-09 and the latest 2026-03-09.
Adma Biologics, INC. (ADMA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-03-13 | S, sale reported on Form 4 | 407,000 | $2.5M | 2024-03-15 |
| 2024-03-14 | S, sale reported on Form 4 | 448,276 | $2.7M | 2024-03-15 |
| 2024-03-15 | S, sale reported on Form 4 | 183,008 | $1.1M | 2024-03-15 |
| 2024-03-18 | S, sale reported on Form 4 | 49,887 | $299.8K | 2024-03-19 |
| 2024-03-19 | S, sale reported on Form 4 | 411,829 | $2.5M | 2024-03-19 |
| 2025-06-12 | S, sale reported on Form 4 | 92,941 | $2.0M | 2025-06-16 |
| 2025-06-13 | S, sale reported on Form 4 | 137,931 | $2.9M | 2025-06-16 |
| 2025-06-16 | S, sale reported on Form 4 | 194,749 | $3.9M | 2025-06-16 |
| 2026-03-05 | P, purchase reported on Form 4 | 7,000 | $109.7K | 2026-03-09 |
| 2026-03-06 | P, purchase reported on Form 4 | 7,000 | $107.7K | 2026-03-09 |
Marker Therapeutics, Inc. (MRKR)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-12-23 | P, purchase reported on Form 4 | 11,085 | $35.5K | 2024-12-26 |
ELEV (ELEV)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1250195) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms